These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21846850)

  • 1. Genomic predictor of survival after chemotherapy for breast cancer.
    Burke HB
    JAMA; 2011 Aug; 306(7):708; author reply 708-9. PubMed ID: 21846850
    [No Abstract]   [Full Text] [Related]  

  • 2. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
    Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
    Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sensitivity of chemotherapy depending on hormone status in breast cancer].
    Ito Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():568-71. PubMed ID: 17679212
    [No Abstract]   [Full Text] [Related]  

  • 4. Quantification of residual risk of relapse in breast cancer patients optimally treated.
    Dieci MV; Arnedos M; Delaloge S; Andre F
    Breast; 2013 Aug; 22 Suppl 2():S92-5. PubMed ID: 24074801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    Thomas ES
    J Clin Oncol; 2008 May; 26(13):2223. PubMed ID: 18445853
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
    Morris PG; Bach PB
    Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
    [No Abstract]   [Full Text] [Related]  

  • 7. High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?
    Regierer AC; Wolters R; Kurzeder C; Wöckel A; Novopashenny I; Possinger K; Wischnewsky MB; Kreienberg R
    Breast Cancer Res Treat; 2011 Jul; 128(1):273-81. PubMed ID: 21210206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy in breast cancer: review of literature.
    Doval DC; Dutta K; Batra U; Talwar V
    J Indian Med Assoc; 2013 Sep; 111(9):629-31. PubMed ID: 24968534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel targeting therapy concept for breast cancer treatment].
    Toi M
    Nihon Yakurigaku Zasshi; 2008 Sep; 132(3):177-9. PubMed ID: 18787301
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms of breast cancer resistance to anthracyclines or taxanes: an overview of the proposed roles of noncoding RNA.
    Li XJ; Zha QB; Ren ZJ; Tang JH; Yao YF
    Curr Opin Oncol; 2015 Nov; 27(6):457-65. PubMed ID: 26371779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2000 EBCTCG overview: a widening gap.
    Chia S; Bryce C; Gelmon K
    Lancet; 2005 May 14-20; 365(9472):1665-6. PubMed ID: 15894082
    [No Abstract]   [Full Text] [Related]  

  • 12. Updates in anti-HER2 combination therapy.
    Burstein H
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):873-4. PubMed ID: 19209136
    [No Abstract]   [Full Text] [Related]  

  • 13. [Advances and perspective in clinical research on breast cancer].
    Xu BH
    Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):881-3. PubMed ID: 18478923
    [No Abstract]   [Full Text] [Related]  

  • 14. [Relationship between Ki67 expression and tumor response to neoadjuvant chemotherapy with anthracyclines plus taxanes in breast cancer].
    Xu L; Liu YH; Ye JM; Zhao JX; Duan XN; Zhang LB; Zhang H; Wang YH
    Zhonghua Wai Ke Za Zhi; 2010 Mar; 48(6):450-3. PubMed ID: 20627009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?
    Mackey JR
    J Clin Oncol; 2011 Apr; 29(12):1504-6. PubMed ID: 21422423
    [No Abstract]   [Full Text] [Related]  

  • 16. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
    Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
    Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer.
    Shien T; Kinoshita T; Seki K; Yoshida M; Hojo T; Shimizu C; Taira N; Doihara H; Akashi-Tanaka S; Tsuda H; Fujiwara Y
    Acta Med Okayama; 2013; 67(3):165-70. PubMed ID: 23804139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medical treatment of early breast cancer: chemotherapy].
    Ejlertsen B; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy regimens in early breast cancer: major controversies and future outlook.
    Joerger M; Thürlimann B
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):165-78. PubMed ID: 23406558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.
    Marino P; Siani C; Bertucci F; Roche H; Martin AL; Viens P; Seror V
    Breast Cancer Res Treat; 2011 Sep; 129(2):401-9. PubMed ID: 21061059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.